At Analona, we fight cancer by developing therapeutic antibodies targets that are essential for tumor cells in pancreatic cancer as well as other major cancers.
We have two programs with two distinct targets:
Target 1 is involved in growth and metastasis
Target 2 regulates critical cancer-driving cellular proteins
We take advantage of the most advanced tools available:
• sophisticated hyperimmune mice and
• patient-derived pancreatic cancer organoids that closely mimic the tumor
Immunization with Targets 1 and 2 have produced high-quality diverse antibody repertoires. The top Target 1 antibodies show strong, dose-dependent tumor cell killing in patient-derived pancreatic cancer organoids.
We are seeking to raise €4 million seed capital to deliver
• Humanized lead antibodies for both targets
• A strong composition-of-matter IP estate
• In vivo proof-of-concept in patient-derived xenograft models
• Designated development candidates
We have strong early data, a clear plan for IP and drug development, and the right team to deliver and welcome interested investors.
